17 May 2019

The future of oncology - unleashing the power lying within us

Conventional anticancer drugs were designed based on the rapid division of tumor cells. However, the malignant transformation is not the only reason for intense proliferation and the collateral damage done to normal cells results in adverse side effects which can even decrease the overall survival. Thus cytotoxic agents are notoriously hard to get through clinical trials resulting in about 95% attrition rates for this drugs [1].

17 May 2019
The future of oncology - unleashing the power lying within us
26 February 2019
Make a difference - share data
29 January 2019
Donate for science
19 November 2018
AACR18 Special Conference Highlights
17 October 2018
Ardigen’s second place solution to the NCI-CPTAC DREAM Proteogenomics Challenge
11 October 2018
Wind of change - review of two groundbreaking articles about microbiome and probiotics.